tipranavirhttp://www.unboundmedicine.com/medline/ebm/research/tipranavirUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.http://www.unboundmedicine.com/medline/ebm/record/19918100/full_citation/P_glycoprotein_multidrug_resistance_associated_proteins_and_human_organic_anion_transporting_polypeptide_influence_the_intracellular_accumulation_of_atazanavir_Janneh O, Anwar T, Jungbauer C, et al. 
P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. [Journal Article]
Antivir Ther 2009; 14(7):965-74.
Abstract | Full CitationValidation of an Electrospray Ionization LC-MS/MS Method for Quantitative Analysis of Raltegravir, Etravirine, and 9 Other Antiretroviral Agents in Human Plasma Samples.http://www.unboundmedicine.com/medline/ebm/record/19865000/full_citation/Validation_of_an_Electrospray_Ionization_LC_MS/MS_Method_for_Quantitative_Analysis_of_Raltegravir_Etravirine_and_9_Other_Antiretroviral_Agents_in_Human_Plasma_Samples_Quaranta S, Woloch C, Paccou A, et al. 
Validation of an Electrospray Ionization LC-MS/MS Method for Quantitative Analysis of Raltegravir, Etravirine, and 9 Other Antiretroviral Agents in Human Plasma Samples. [JOURNAL ARTICLE]
Ther Drug Monit 2009 Oct 27.
Abstract | Full Citation | Find Related Articles Trends in uptake of recently approved antiretrovirals within a national healthcare system.http://www.unboundmedicine.com/medline/ebm/record/19863620/full_citation/Trends_in_uptake_of_recently_approved_antiretrovirals_within_a_national_healthcare_system_Belperio P, Mole L, Boothroyd D, et al. 
Trends in uptake of recently approved antiretrovirals within a national healthcare system. [JOURNAL ARTICLE]
HIV Med 2009 Oct 23.
Abstract | Full Citation | Find Related Articles Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain.http://www.unboundmedicine.com/medline/ebm/record/19842792/full_citation/Changes_in_Drug_Resistance_Patterns_following_the_Introduction_of_HIV_Type_1_Non_B_Subtypes_in_Spain_De Mendoza C, Garrido C, Poveda E, et al. 
Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain. [Journal Article]
AIDS Res Hum Retroviruses 2009 Oct; 25(10):967-72.
Abstract | Full CitationComparison of the pharmacokinetics of apricitabine in the presence and absence of ritonavir-boosted tipranavir: a phase I, open-label, controlled, single-centre study.http://www.unboundmedicine.com/medline/ebm/record/19813775/full_citation/Comparison_of_the_pharmacokinetics_of_apricitabine_in_the_presence_and_absence_of_ritonavir_boosted_tipranavir:_a_phase_I_open_label_controlled_single_centre_study_Cox S, Southby J, Linet O, et al. 
Comparison of the pharmacokinetics of apricitabine in the presence and absence of ritonavir-boosted tipranavir: a phase I, open-label, controlled, single-centre study. [Journal Article]
Clin Drug Investig 2009; 29(11):721-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles Diagnosis and Monitoring of HIV-1 Group O-Infected Patients in Cameroun.http://www.unboundmedicine.com/medline/ebm/record/19770803/full_citation/Diagnosis_and_Monitoring_of_HIV_1_Group_O_Infected_Patients_in_Cameroun_Vessière A, Rousset D, Kfutwah A, et al. 
Diagnosis and Monitoring of HIV-1 Group O-Infected Patients in Cameroun. [JOURNAL ARTICLE]
J Acquir Immune Defic Syndr 2009 Sep 17.
Abstract | Full Citation | Find Related Articles Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.http://www.unboundmedicine.com/medline/ebm/record/19751502/full_citation/Impact_of_first_line_protease_inhibitors_on_predicted_resistance_to_tipranavir_in_HIV_1_infected_patients_with_virological_failure_Hsieh SM, Chang SY, Hung CC, et al. 
Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure. [JOURNAL ARTICLE]
BMC Infect Dis 2009 Sep 14; 9(1):154.
Abstract | Full Citation | Find Related Articles Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.http://www.unboundmedicine.com/medline/ebm/record/19726139/full_citation/Pharmacokinetic_interactions_between_buprenorphine/naloxone_and_tipranavir/ritonavir_in_HIV_negative_subjects_chronically_receiving_buprenorphine/naloxone_Bruce RD, Altice FL, Moody DE, et al. 
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. [JOURNAL ARTICLE]
Drug Alcohol Depend 2009 Aug 31.
Abstract | Full Citation | Find Related Articles Lack of effect of efavirenz on the pharmacokinetics of tipranavir/ritonavir (TPV/r) in healthy volunteers.http://www.unboundmedicine.com/medline/ebm/record/19721063/full_citation/Lack_of_effect_of_efavirenz_on_the_pharmacokinetics_of_tipranavir/ritonavir__TPV/r__in_healthy_volunteers_la Porte CJ, Sabo JP, Béïque L, et al. 
Lack of effect of efavirenz on the pharmacokinetics of tipranavir/ritonavir (TPV/r) in healthy volunteers. [JOURNAL ARTICLE]
Antimicrob Agents Chemother 2009 Aug 31.
Abstract | Full Citation | Publisher Full Text | Find Related Articles The history of antiretrovirals: key discoveries over the past 25 years.http://www.unboundmedicine.com/medline/ebm/record/19714702/full_citation/The_history_of_antiretrovirals:_key_discoveries_over_the_past_25_years_De Clercq E 
The history of antiretrovirals: key discoveries over the past 25 years. [JOURNAL ARTICLE]
Rev Med Virol 2009 Aug 27; 19(5):287-299.
Abstract | Full Citation